Enanta Pharmaceuticals (ENTA) Stock News, Dec 2024-Jul 2025

The FDA has approved an expanded indication for MAVYRET (glecaprevir/pibrentasvir), making it the first and only 8-week treatment approved for both acute and chronic Hepatitis C Virus (HCV) infection. Developed through a partnership between Enanta Pharmaceuticals (NASDAQ:ENTA) and AbbVie, MAVYRET demonstrated a 96% cure rate in clinical trials. The treatment is approved for adults and children aged 3 and older, with or without compensated cirrhosis. The FDA granted Breakthrough Therapy Designation based on Phase 3 trial results showing high efficacy with mild to moderate adverse events. Over one million chronic HCV patients have been treated with MAVYRET, and this expansion allows immediate treatment upon diagnosis, potentially preventing progression to chronic disease and supporting global HCV elimination goals by 2030.

Enanta Pharmaceuticals (NASDAQ: ENTA), a clinical-stage biotech company focused on developing small molecule drugs for viral infections and immunological diseases, has announced that its President and CEO, Jay R. Luly, Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2025, at 8:10 a.m. ET in New York. Investors can access the live webcast through Enanta's website, and a replay will be available for at least 30 days after the event.

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q2 2025 financial results with key developments in its virology and immunology pipeline. The company achieved target enrollment of 180 patients in RSVHR Phase 2 study of zelicapavir for RSV treatment, with topline data expected in late Q3 2025. Financial highlights include revenue of $14.9 million from MAVYRET royalties (down from $17.1M in Q2 2024), and a net loss of $22.6 million ($1.06 per share). Cash position stands at $193.4 million, further strengthened by a $33.8 million federal tax refund received in April 2025. The company's pipeline progress includes STAT6 program advancement with plans for development candidate selection in 2H 2025, and ongoing IND enabling studies for KIT inhibitor EPS-1421. Enanta expects current financial resources to fund operations into fiscal 2028.

Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that data from their Phase 2a human challenge study of EDP-323, a first-in-class oral RSV treatment, will be presented at ESCMID Global 2025 in Vienna, Austria. The presentation will showcase results from the study, which were initially announced in September 2024, including new data on respiratory mucus production.

EDP-323 is a non-nucleoside small-molecule inhibitor targeting the RSV polymerase (L-protein). The ePoster presentation, titled 'EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study,' will be presented by Dr. John P. DeVincenzo on April 13, 2025, at 8:30 a.m. CEST.

Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company focused on developing small molecule drugs for virology and immunology indications, has announced its upcoming participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference.

The management team will deliver their presentation on Thursday, March 27, 2025, at 11:00 a.m. ET. Interested parties can access the live webcast through the 'Events and Presentations' section on the 'Investors' page of Enanta's website. A replay will be available post-presentation and remain accessible for a minimum of 30 days.

Enanta Pharmaceuticals (NASDAQ:ENTA) announced its upcoming presentations at the 13th International RSV Symposium (RSV 2025) in Iguazu Falls, Brazil, from March 12-15. The company will showcase four presentations highlighting its respiratory syncytial virus (RSV) program:

The main oral presentation will feature results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, scheduled for March 14. A late-breaker poster will present data from a Phase 2 study of zelicapavir, an N-protein inhibitor, for RSV treatment in young children.

Two additional poster presentations will focus on: (1) distinctions among fusion, N, and L inhibitors regarding preclinical antiviral effect and resistance profiles, and (2) PK and PK/PD results from the EDP-323 Phase 2 human challenge study. All presentations will be delivered at the Bourbon Cataratas do Iguazu venue.

Enanta Pharmaceuticals (NASDAQ:ENTA) reported financial results for Q1 FY2025 ended December 31, 2024. Total revenue was $17.0 million, down from $18.0 million in Q1 FY2024, consisting of royalties from MAVYRET®/MAVIRET® sales. The company reported a net loss of $22.3 million ($1.05 per share), compared to a $33.4 million loss ($1.58 per share) in the prior year.

Research and development expenses decreased to $27.7 million from $36.4 million, while G&A expenses reduced to $12.8 million from $16.5 million. The company maintains a strong financial position with $216.7 million in cash and marketable securities, expected to fund operations into fiscal 2028.

Key developments include ongoing recruitment for the RSVHR Phase 2 study of zelicapavir, with topline data expected in Q3 2025, and advancement of immunology portfolio including KIT inhibitor EPS-1421 and STAT6 program development.

Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that its President and CEO, Jay R. Luly, Ph.D., will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2024, at 8:15 a.m. PT in San Francisco, CA.

The clinical-stage biotechnology company, which focuses on developing small molecule drugs for virology and immunology indications, will provide a live webcast of the presentation through the "Events and Presentations" section on the "Investors" page of their website. The webcast recording will remain available for a minimum of 30 days following the presentation.

Enanta Pharmaceuticals (NASDAQ: ENTA) announced that the United States District Court of Massachusetts has ruled against them in a patent infringement lawsuit against Pfizer. The Court granted Pfizer's summary judgment motion, declaring Enanta's '953 Patent invalid. This patent was related to Pfizer's COVID-19 antiviral, Paxlovid.

The Court also denied Enanta's partial motion for summary judgment of infringement. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit. Despite the ruling, the company maintains its commitment not to impede Paxlovid's production, sale, or distribution.